VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Core Insights - VolitionRx Limited is participating in the 14th Annual LifeSci Partners Corporate Access Event on January 15, 2025, in San Francisco, coinciding with the J.P. Morgan Health Care Conference [1][3] - The company has engaged LifeSci Advisors, LLC to enhance investor relations and awareness, particularly focusing on institutional money managers and family funds in the life sciences sector [1][3][4] - In 2024, Volition has achieved significant milestones, including the launch of the Nu.Q® Vet Cancer Test in the U.S. and Europe [2][3] Company Overview - Volition is a multinational company dedicated to advancing epigenetics, aiming to improve outcomes for patients and animals through early disease detection and monitoring [5][6] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers and conditions related to NETosis, such as sepsis [6] Strategic Focus - Volition's research and development activities are primarily based in Belgium, with additional offices in the U.S., London, and Singapore [7] - The company is focused on creating financial and operational milestones in the human health space for cancer and sepsis in 2025 [3]